Primary Progressive Multiple Sclerosis (PPMS) Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsigh
(Albany, US) DelveInsight has launched a new report on
"Primary
Progressive Multiple Sclerosis (PPMS) - Market Insights, Epidemiology, and
Market Forecast-2030".
DelveInsight's "Primary
Progressive Multiple Sclerosis (PPMS) - Market Insights, Epidemiology, and
Market Forecast-2030" report delivers an
in-depth understanding of the Primary Progressive Multiple Sclerosis (PPMS),
historical and forecasted epidemiology as well as the Primary Progressive
Multiple Sclerosis (PPMS) market trends in the United States, EU5 (Germany,
Spain, Italy, France, and United Kingdom) and Japan.
·
As per the National Multiple Sclerosis Society,
about 15% of the total estimated MS patients in the United States with multiple
sclerosis (MS) have the primary progressive form of the disease (PPMS).
·
According to a study by Costa-ArpĂn et al.
(2020), in a Spanish cohort, 71.17% had relapsing-remitting MS, 16.55%
secondary progressive MS, 7.59% primary progressive MS, and 0.69% progressive
relapsing MS.
·
As per the estimates provided by Columbia
University Medical Center (2018), on average, people with the primary
progressive form of MS start having symptoms between ages 35 and 39.
·
According to a review article titled “Primary
Progressive Multiple Sclerosis” published by Giovannon et al. (2012), the
female to male ratio is generally 1:1 with regard to PPMS and 2 or even 3:1 for
relapse onset disease. As seen by changes in the sex ratio, the increasing
female preponderance of MS seems to be driven by relapse-onset disease, with
the incidence of PPMS remaining relatively constant.
View Report: https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market
Request for free
sample report: https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-market
- The
report covers the descriptive overview of Primary Progressive Multiple
Sclerosis (PPMS), explaining its causes, signs and symptoms,
pathophysiology, diagnosis and currently available therapies
- Comprehensive
insight has been provided into the Primary Progressive Multiple Sclerosis
(PPMS) epidemiology and treatment in the 7MM
- Additionally,
an all-inclusive account of both the current and emerging therapies for
Primary Progressive Multiple Sclerosis (PPMS) are provided, along with the
assessment of new therapies, which will have an impact on the current
treatment landscape
- A
detailed review of Primary Progressive Multiple Sclerosis (PPMS) market;
historical and forecasted is included in the report, covering drug
outreach in the 7MM
- The
report provides an edge while developing business strategies, by
understanding trends shaping and driving the global Primary Progressive Multiple
Sclerosis (PPMS) market
View Report: https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market
Request for free
sample report: https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-market
Primary-Progressive
Multiple Sclerosis (PPMS)
is a neurodegenerative disease that interferes with the brain's ability to
control the body. There are four main types of MS: relapsing-remitting MS
(RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), and progressive-relapsing
MS. Each type might be mild, moderate, or severe. PPMS is characterized by
worsening neurologic function (accumulation of disability) from the onset of symptoms,
without early relapses or remissions.
PPMS can be further characterized at different points in
time as either active (with an occasional relapse and/or evidence of new MRI
activity) or not active, as well as with progression (evidence of disease
worsening on an objective measure of change over time, with or without relapse
or new MRI activity) or without progression.
The occurrence and severity of PPMS symptoms vary with each
person. Symptoms include headaches, pain in the legs and feet, back pain,
muscle spasms, trouble in walking, vision problems, etc. In addition, this
condition affects men and women equally.
·
MedDay Pharma
·
MediciNova
·
Mapi Pharma
·
Brainstorm-Cell Therapeutics
·
And Many Others
·
GA Depot
·
MN-166
·
MD1003
·
NurOwn
·
And Many Others
View Report: https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market
Request for free
sample report: https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-market
1. Key Insights
2. Executive Summary
of Primary Progressive Multiple Sclerosis (PPMS)
3. Competitive
Intelligence Analysis for Primary Progressive Multiple Sclerosis (PPMS)
4. Primary
Progressive Multiple Sclerosis (PPMS): Market Overview at a Glance
4.1. Primary Progressive Multiple Sclerosis (PPMS) Total
Market Share (%) Distribution in 2017
4.2. Primary Progressive Multiple Sclerosis (PPMS) Total
Market Share (%) Distribution in 2030
5. Primary
Progressive Multiple Sclerosis (PPMS): Disease Background and Overview
6. Patient Journey
7. Primary
Progressive Multiple Sclerosis (PPMS) Epidemiology and Patient Population
8. Treatment
Algorithm, Current Treatment, and Medical Practices
8.1. Primary Progressive Multiple Sclerosis (PPMS) Treatment
and Management
8.2. Primary Progressive Multiple Sclerosis (PPMS) Treatment
Algorithm
9. Unmet Needs
10. Key Endpoints of
Primary Progressive Multiple Sclerosis (PPMS) Treatment
11. Marketed
Products
List to be continued in report
12. Emerging
Therapies
List to be continued in report
13. Primary
Progressive Multiple Sclerosis (PPMS): Seven Major Market Analysis
13.1. Key Findings
13.2. Primary Progressive Multiple Sclerosis (PPMS) Market
Size in 7MM
13.3. Primary Progressive Multiple Sclerosis (PPMS) Market
Size by Therapies in the 7MM
14. Attribute
analysis
15. 7MM: Market
Outlook
16. Access and
Reimbursement Overview of Primary Progressive Multiple Sclerosis (PPMS)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight
Capabilities
22. Disclaimer
23. About
DelveInsight
About DelveInsight
DelveInsight is a premier Business Consulting and Market
Research firm focused exclusively on the life science segment. With a wide
array of smart end-to-end solutions, the firm helps the global Pharmaceutical
and Bio-Tech companies formulate prudent business decisions for
Browse through our vast repository from here.
Media Contact
Company Name: DelveInsight
Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
Comments
Post a Comment